Efficacy observation of thalidomide combined with TP regimen in treatment of advanced gastric cancer
10.3760/cma.j.issn.1006-9801.2019.09.008
- VernacularTitle: 沙利度胺联合TP方案治疗晚期胃癌效果观察
- Author:
Mengke NIU
1
;
Wenying DENG
;
Ning LI
;
Suxia LUO
Author Information
1. Department of Gastroenterology, the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou 450000, China
- Publication Type:Journal Article
- Keywords:
Stomach neoplasms;
Thalidomide;
Antineoplastic combined chemotherapy protocols;
Comparative effectiveness research
- From:
Cancer Research and Clinic
2019;31(9):610-613
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the clinical efficacy of thalidomide combined with TP regimen (taxol+cisplatin) in treatment of advanced gastric cancer.
Methods:A total of 60 patients with advanced gastric cancer in the Affiliated Cancer Hospital of Zhengzhou University from February 2016 to March 2018 were enrolled. The patients were divided into two groups by using random number table method: the observation group (32 cases) taking thalidomide, oral administration 100 mg based on TP regimen before going to bed; the control group (28 cases) taking TP regimen chemotherapy only. Both groups received 75 mg/m2 doses of cisplatin, intravenous infusion, 25 mg/m2 per day, for 3 d. Paclitaxel dose was 150 mg/m2, intravenous infusion for 1 day, 3-week was one course, and the efficacy was evaluated after at least 2 course of treatment.
Results:The incidence of gastrointestinal adverse reactions including nausea and vomiting was 21.8% (7/32) in the observation group, and was 64.3% (18/28) in the control group, and the difference was statistically significant (χ 2 = 11.051, P = 0.001), but there were no statistically significant differences in the incidence of morning faint, constipation, bone marrow suppression, liver and kidney injury and other adverse reactions between the two groups (all P > 0.05). The effective rates in the observation group and the control group were 43.8% (14/32) and 39.3% (11/28), respectively, and the disease control rates in the observation group and the control group were 84.4% (27/32) and 78.6% (22/28), respectively. There were no significant differences in the effective rates and the disease control rates between the two groups (χ 2 = 0.122, P = 0.726; χ2 = 0.336, P = 0.562). The improvement and significant improvement rate of sleeping quality, pain, Eastern Cooperative Oncology Group (ECOG) score was 71.9% (23/32), 53.1% (17/32), 56.2% (18/32), respectively in the observation group, and 17.9% (5/28), 14.3% (4/28), 21.4% (6/28), respectively in the control group, and the difference between the two groups was statistically significant (all P < 0.05).
Conclusions:Thalidomide combined with TP regimen in treatment of advanced gastric cancer patients can improve the efficacy of chemotherapy and the quality of life. It also has a good tolerance to side effects.
